Thank you. Welcome to Manulife's earnings conference call to discuss our third quarter 2025 financial and operating results, as well as our refreshed strategy that was announced yesterday afternoon.

Our earnings materials, including webcast slides for today's call, are available in the Investor Relations section of our website at manulife.com. In addition, I would like to note that a video recording of our refreshed strategy presentation and related materials are also available in the same section of our website.

Before we start, please refer to slide 2 for a caution on forward-looking statements, and slide 33 for a note on the non-GAAP and other financial measures used in this presentation. Please note that certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from what is stated.

Turning to slide 4, we'll begin today's presentation with Phil Witherington, our President and Chief Executive Officer, who will provide a highlight of our third quarter 2025 results and a strategic update, including an overview of our refreshed strategy. Following Phil, Colin Simpson, our Chief Financial Officer, will discuss the company's financial and operating results in more detail.

After their prepared remarks, we will move to the live Q&A portion of the call. With that, I would like to turn the call over to Phil.

Thanks, Hung. Thank you, everyone, for joining us today.

Before I start, I'd like to thank Marc Costantini, who's with us on the call today, for his outstanding contributions to Manulife throughout his career at the company, and wish him well in the next chapter of his career. Marc's two stints with Manulife total more than 25 years, and in his most recent role as Global Head of Inforce Management, he had an immense impact in a short period of time, including the completion of several monumental reinsurance transactions, which unlocked significant value for shareholders.

While we're sad to see him go, we know he will flourish as a CEO, and we wish him nothing but the best. Inforce management has been embedded as a capability in our organization, and it will remain an important enabler of our commercial success.

Naveed Irshad, President and CEO of Manulife Canada, has taken on an expanded role and assumed responsibility for inforce management and reinsurance globally, while continuing to lead the Canada segment. Shifting back to the purpose of today's call, yesterday, we announced our third quarter 2025 financial results.

At the same time, we unveiled our refreshed enterprise strategy, which builds on our strengths, is growth focused, and is anchored in our ambition to be the number one choice for customers. Materials related to our refreshed strategy, including a video, are available in the Investor Relations section of our website, but I want to highlight a few key takeaways.

To deliver on our ambition, drive sustainable growth for the long term, and build on our total shareholder return momentum, we're pleased to introduce new and elevated strategic priorities. Maintaining a diversified and balanced portfolio is important to us, as it provides resilience and access to multiple sources of growth without overreliance on any single market.

We continue to be well positioned to capture the exceptional growth opportunities across Asia and Global WAM, and I'm pleased to share that we have reached an agreement with Mahindra, a leading conglomerate and consumer brand in India, to form a joint venture to enter the India insurance market, subject to regulatory approvals. Mahindra is an incredibly strong and trusted partner with whom we have an existing asset management relationship, and I'm excited about expanding our partnership further.

Our continued focus on Asia and Global WAM will be accompanied by deliberate investments to enhance and strengthen our leadership position in our home market and maintain a scaled presence in the US, which remains the largest insurance market and the largest economy in the world. We will also leverage our early leadership in AI to become a truly AI-powered organization, and we will utilize our strengths in product, digital innovation, and partnerships to become the most trusted partner for our customers' health, wealth, and financial wellbeing.

These efforts will be further enabled through superior distribution, making it easier for customers, agents, and partners to engage with us, and, of course, through our winning team and culture, which is critical to every aspect of the execution of our strategy. At our Investor Day in 2024, we announced various key performance indicators and targets, including total shareholder return, employee engagement, and Net Promoter Score, which we remain focused on delivering.

I am incredibly excited about this next chapter for Manulife, and I'm confident that executing on our strategy will further strengthen our ability to deliver on both our 2027 financial targets and sustain our growth for the next decade and beyond. Moving on to our quarterly results on slide 7, which reflect our continued focus on execution and demonstrate the strength and diversity of our businesses.

We generated strong insurance new business performance this quarter, with each insurance segment delivering growth of 15% or greater in new business CSM, providing clear evidence of our future earnings potential. While Global WAM experienced net outflows of $6.2 billion, which Colin will discuss in more detail shortly, it continued to generate positive operating leverage with margin expansion year over year.

From a profitability standpoint, core EPS grew 16% from the prior year, supported by a record level of core earnings, reflecting strong underlying business growth in Asia, Global WAM, and Canada segments, along with other factors, which Colin will talk about further. Our strong core earnings generation contributed to third quarter core ROE of 18.1%, demonstrating that our core ROE target of 18%-plus by 2027 is within reach, and we remain confident that we'll deliver on it.

Our balance sheet remains strong, with a LICAT ratio of 138% and a leverage ratio of 22.7%, and we generated another quarter of book value per share growth with an increase of 7% from the prior year, while continuing to return a significant amount of capital to shareholders. On to slide 8, I'd like to dive a little deeper into the recent performance of our high-potential businesses, particularly Asia and Global WAM, as they remain critical elements of our refreshed enterprise strategy.

Over the past several years, both segments demonstrated strong track records of generating consistent growth and resilience through a volatile operating environment. The performance from both Asia and Global WAM has meant that on a year-to-date basis, our highest-potential businesses are contributing 76% of core earnings, exceeding our 2025 target of 75%.

Asia had another outstanding quarter of growth, delivering a 29% year-on-year increase in core earnings to a record level. Our NBV margin also remained resilient, improving year on year to 39%, backed by the solid growth in new business during the quarter.

In Global WAM, we also delivered a record level of core earnings, maintaining another quarter of strong growth, and this was our eighth consecutive quarter of double-digit pretax growth from the prior year. Our focus on disciplined growth with proactive expense management enabled us to continue to generate positive operating leverage and steadily increase our core EBITDA margin, which expanded by 310 basis points year on year to 30.9% this quarter.

These are great results, and as I reflect on the future and what comes next, I'm confident that our refreshed strategy, supported by clear priorities, will position us to deliver sustainable growth and achieve our new ambition to be the number one choice for customers. With that, I'll hand it over to Colin to discuss our quarterly results in more detail.

Colin.

Thanks, Phil. The third quarter was indeed a strong quarter for Manulife, where we continued to demonstrate the ongoing strength, quality, and resilience of our business.

Let's begin on slide 10, where we talk about our growth in the quarter. The momentum in our insurance new business performance continued in the third quarter.

Our APE sales increased 8% from the prior year, with strong contributions from our North American businesses. This resulted in continued growth in our value metrics, with 25% and 11% growth in new business CSM and new business value, respectively.

Growth in new business CSM was strong, with each insurance segment delivering growth of 15% or greater compared to the prior-year quarter. In fact, our total new business CSM increased over 20% year over year for the fifth consecutive quarter, further highlighting the strength of our diversified franchise and providing an encouraging read-through to the future earnings potential of each business.

Headwinds in North American retail and our US retirement channel led to net outflows of $6.2 billion for Global WAM, following six consecutive quarters of positive net flows. In our retail business, this was primarily due to continued pressure in the intermediary and wealth channels, while the headwinds in our US retirement business were anticipated as elevated markets resulted in higher absolute level of participant withdrawals.

Moving on to slide 11, which summarizes the main earnings drivers when compared to the same period last year. We continued to see growth in our insurance businesses in Asia and Canada, which contributed to a higher insurance service result.

We also saw a net favorable impact from the annual actuarial review of methods and assumptions, or basis change, during the quarter. Although this was partially offset by unfavorable claims experience in the US, I would note that US insurance experience improved from the previous quarter, even though claims severity remained somewhat elevated on a small number of policies, in contrast with last year's favorable experience.

Moving down on the DOE table, you will note a year-over-year improvement in our net investment results, mainly due to a release in the expected credit loss, or ECL provision, driven by updates to our parameters and models compared with an increase in the provision in the prior year. Note that we continue to expect an ECL charge of $30 million to $50 million per quarter on average, and year to date, the increase in ECL is $86 million post tax.

Excluding the impact of the ECL, our core earnings growth would have been 6% compared with the prior year. Global WAM continues to be a significant contributor to our core earnings and reported a 19% growth in pretax core earnings this quarter.

You will notice the lower income tax amount despite the growth in our core earnings. This is mainly driven by an adjustment to our year-to-date withholding tax accrual, reflecting the use of our internal funding for the CQS acquisition.

Finally, I would also add that the most recent US reinsurance transaction with RGA reduced our core earnings by $12 million across multiple lines of the DOE. Turning to slide 12.

Core EPS increased 16% from the prior year, reflecting the strong double-digit growth in core earnings, as well as the impact of share buybacks. In fact, even after adjusting for ECL, we saw strong growth of 11%.

We reported $1.8 billion of net income this quarter, which reflects neutral market experience, where a $291 million gain from higher-than-expected public equity returns was offset by a charge of $289 million in our alternative portfolio from lower-than-expected returns. Our alternative performance was primarily impacted by lower-than-expected returns on private equity and commercial real estate investments, as well as our timber assets, reflecting a recent decline in commodity prices.

During the quarter, we also completed our annual basis change, which included our comprehensive triennial review of our US long-term care business, or LTC. The basis change resulted in a net favorable impact of a $605 million decrease in overall pretax fulfillment cash flows, which comprised a $1.1 billion increase in CSM, partially offset by a modest decrease in net income of $216 million post tax, as well as a small impact to OCI.

I would also note that the overall impact of the LTC study was slightly favorable, largely driven by favorable rerate experience and assumed future premium rate increases, as well as updates to reflect higher terminations, partially offset by higher utilization of benefits given the higher cost of care. The premium increases included amounts tied to future asks, as well as approvals in excess of our prior assumptions, illustrating our conservatism in embedding these into our reserves.

It is important to note the favorable net impact from the basis change further validates the prudence of our reserves. We reported a modest favorable impact on core earnings this quarter, and we also expect a similarly modest positive impact on core earnings going forward.

More information on the basis change is available in the appendix of this presentation. Moving to the segment results, we'll start with Asia on slide 13, where we generated solid growth across all new business metrics despite a very strong prior-year comparable.

APE sales increased 5% from the prior year, led by strong growth in Asia Other. While Hong Kong sales declined year on year compared to a very strong prior-year quarter, we generated sequential growth of 4%.

The overall increase in sales contributed to solid growth in value metrics, with new business CSM and new business value increasing 18% and 7%, respectively. All of this, together with improved product mix, drove NBV margin expansion from the prior year of 2.5 percentage points to 39%.

Asia core earnings also delivered another strong quarter of strong year-on-year growth, increasing 29% as we benefited from continued business growth momentum, the net favorable impact of basis change, and improved insurance experience, as well as a release in the ECL provision compared with an increase in the prior-year quarter. Over to Global WAM on slide 14.

Global WAM continued to build on its growth momentum, delivering record-level core earnings with a solid 9% increase year on year. This was again supported by higher average AUMA and higher performance fees, as well as continued expense discipline, partially offset by lower favorable tax true-ups and tax benefits.

On a pretax basis, we achieved our eighth consecutive quarter of double-digit year-over-year growth, delivering a 19% increase in the third quarter. Net flows were challenged this quarter, resulting in net outflows of $6.2 billion.

Our retail business saw net outflows of $3.9 billion related to our North American intermediary and wealth channels, followed by net outflows of $1.6 billion in our retirement business. Here, we saw higher outflows due to market appreciation, as people generally had higher account balances, which resulted in ordinary course withdrawals also being higher.

Our institutional business also saw modest net outflows of $0.7 billion, and with the close of our third infrastructure fund in the quarter, we expect this to be a positive contributor to flows as money is deployed over the course of next year. Despite the challenges in our net flows, we delivered another quarter of positive operating leverage, with core EBITDA margin of 30.9%, which expanded 310 basis points from the prior year, or 80 basis points sequentially, backed by our continued proactive expense management.

With regards to eMPF, I can confirm we officially commenced our onboarding to the new platform in Hong Kong on November 6, and thus expect to reflect an impact to core earnings in our retirement business starting in the fourth quarter. Next, let's head over to Canada on slide 15, where we delivered another quarter of solid results.

APE sales increased 9% from the prior year, reflecting continued double-digit growth in our individual insurance business, primarily due to higher par sales. Our individual insurance business was the key contributor to a strong new business CSM growth of 15% year on year, as our group insurance business does not generate CSM.

We also delivered a solid 4% year-over-year growth in core earnings, driven by higher investment spreads, as well as continued growth in our group insurance business and favorable insurance experience in individual insurance. The basis change provided additional uplift, but these drivers were partially offset by less favorable insurance experience in group insurance.

Lastly, our US segment's results on slide 16. In the US, we delivered another quarter of strong APE sales growth of 51%, fueled by higher, broad-based demand for our suite of products.

This momentum led to more than doubling of our new business CSM and a 53% increase in new business value. Core earnings decreased 20% year on year, primarily due to unfavorable life insurance claims experience this quarter compared with favorable experience a year ago, along with lower expected investment earnings.

These impacts were partially offset by a release in the ECL provision compared with an increase in the prior year, as well as favorable lapse experience in our life business. While large claims variability presented challenges, the fundamentals of our US business remain strong and position us well for steady earnings in the long term.

Our confidence is reinforced by the sequential improvement in core earnings and the continued strong growth in our new business metrics this quarter, which bodes well for our future earnings in the segment. Looking beyond our earnings, it's worth noting our overall LTC insurance experience was once again modestly positive, including favorable incidence reported in the CSM.

Bringing you to our book value on slide 17. Even after returning nearly $4 billion of capital to shareholders year to date through dividends and share buybacks, we continued to grow our adjusted book value per share, which was up 12% from the prior-year quarter to $38.22.

On a standalone quarter basis, we continued to demonstrate our strong cash generation capability and returned over $1.3 billion of capital to shareholders, including both dividends and share buybacks during the period. As Phil mentioned in our refreshed strategy update, we expect our remittances for 2025 to be approximately $6 billion, putting us well on our way to achieving our cumulative 2027 target of at least $22 billion.

Let's now move to our balance sheet on slide 18. Our LICAT ratio remained strong at 138%, providing a $26 billion buffer above the supervisory target ratio.

Our financial leverage ratio improved sequentially, as well as year on year, standing at 22.7% and remaining well below our medium-term target of 25%. Together, these metrics highlight the strength and stability of our robust capital position and balance sheet, which provide ample financial flexibility to drive future growth.

Finally, moving to slide 19, which summarizes the progress against our 2027 and medium-term targets. I'm pleased with our overall financial performance this quarter, in particular with record core earnings supported by our continued top-line momentum, despite some headwinds that impacted our net flows and alternative performance.

This quarter, we also generated core ROE of 18.1% with a meaningful expansion of 1.5 percentage points year on year. As Phil highlighted in our refreshed strategy update, we have a clear path to achieving our 2027 core ROE target of 18%-plus, and I'm confident in our ability to do so.

Overall, our third quarter results reflect the ongoing strength of our underlying business performance and the quality of our portfolio, and when combined with our focused execution against refreshed strategic priorities, I'm excited for the future and the opportunities that lie ahead. This concludes our prepared remarks.

Before we move to the Q&A session, I would like to remind each participant to adhere to a limit of two questions, including follow-ups, and to requeue if they have additional questions. Operator, we will now open the call to questions.

Good morning. Phil, I'm very intrigued with the venture that you announced in India.

Was hoping you might be able to give us a couple more details in terms of what type of products you think you're going to be offering, what you bring to the table in what I believe is a very competitive marketplace, and then finally, the regulatory approval process. How long do you think that'll take before you can actually open shop for business?

John, this is Phil. Thanks for the question and the first question today.

Certainly the announcement we made yesterday of our intention to enter the India market through a JV with Mahindra is very exciting. We've been looking at an India market entry from an insurance perspective for many years and have been really observing the environment to wait for the right moment.

What we've seen in recent years is that the regulatory environment has moved favorably, the digital infrastructure within India has moved very favorably, there's been consistent economic growth and market maturity within the insurance sector. As well as that, there has been a notable increase in wealth across the India population, and that creates insurance needs and provides an ability to purchase insurance products.

I think a really important component of our entry strategy here is really moving with the right partner, and Mahindra, who's been our partner on the asset management side since 2020, is a fantastic partner and has not only substantial local knowledge, but a strong brand, as well as a distribution infrastructure. In terms of some of the specific questions that you asked on what we bring to the table, we bring our global expertise in the insurance sector to this partnership.

It's not only about product development, but it's also in aspects such as risk management, which are so important to managing insurance businesses. It's too early to get into a topic such as what the products will look like.

I expect it will take in the order of 12 to 18 months to get this operation off the ground and up and running, including the regulatory approval process that you referenced. I look forward to providing updates along the way.

Thanks for the color, Phil. I'll requeue.

Thanks, John.

Hi, good morning. Wanted to see if you could talk a little bit more about what you're seeing in some of your Asia markets and growth has been pretty good.

What's your outlook for continued strength of sales over the next couple years?

Thanks, Alex. It's Steve Finch here.

I can take that. As you noted, we've had some strong momentum in results in Asia, as Colin covered.

We saw continued solid momentum in sales growth in the quarter with our new business value metrics up 7% on NBV, 18% up on CSM, new business CSM, which bodes well for our future earnings. We've seen broad-based success across multiple markets, continued strength in the value metrics in Hong Kong.

Then in Asia Other, we had a strong result in our China business, as well as continued momentum in Singapore, our Indonesia agency, and as well as our bank partner in the Philippines. We've continued to see broad-based success.

What we see is the market fundamentals and customer demand remain strong. Aligned with the strategy that Phil updated on, we're continuing to make the investments for growth, and we're well positioned to capitalize in markets across the region.

That's helpful. Thank you.

For the next question, I wanted to ask about your private credit exposure. See if you could put numbers around some of the different forms of private credit you have, and also just ask if you have any comments just on some of the comments that have been made by industry participants out there that have been a little more critical of private credit recently.

Hey, Alex. It's Trevor.

Thanks for the question. Yes, in terms of private credit, just for context, our below-investment-grade private credit portfolio is around $4 billion Canadian.

It's a little bit less than about 1% of our general account assets. The strategy's largely focused on middle-market lending to private equity sponsored companies.

It's pretty diverse by issuer, sector, and sponsor, and we do manage and underwrite these assets in-house. I would say we see our participation as kind of being on the lower end of the risk spectrum.

Our performance has actually been quite strong, even with COVID, even with the rate increases, and the credit experience has actually been I think well within our loss assumptions. We are actually quite happy with the strategy.

In terms of use of private credit, I would say we're always looking at new asset classes to diversify the balance sheet. I think given the nature of private credit, the ratings, the term, and the fact that it's floating rate, the most natural home for us in the balance sheet is probably our par and adjustable liabilities where investment experience is passed back to the policyholder.

I think we might look to add a little bit more there where we thought it was sort of appropriate for the balance sheet.

Okay. Thank you.

Good morning. First question is for the GWM business, the mandatory provident fund fee changes they're going to start having an effect in Q4.

We all are aware of this, but you alluded to some actions you would take and you'd contemplated this regulatory change when you laid out your 2027 vision. Maybe you can shed a bit more light on what some of these offsets are, how impactful they could be, when they could become effective, I guess.

Thanks, Gabriel. It's Paul Lorentz here.

Just on that, the guidance we've provided of around $25 million USD a quarter remains intact once we get through the entire transition. We did transition earlier this month.

It will take us some time to decommission systems, obviously reduce our FT footprint there because we're no longer servicing the business. You'd expect to see some of that come through, that those costs continue into Q1, and then we would expect most of those to disappear into Q2.

In terms of outlook for Q4, we did end the quarter with higher AUMA versus the average, there is a little bit of upside there in terms of revenue, but that'd be offset by the eMPF coming in for two months of the quarter. Then in Q1, we would obviously get the full runway coming through.

Just to put a finer point on it, are you expecting to fully offset at some point in the future or not?

Most of the expense actions we took were upfront to try and get ahead of it. That's why we've seen such an improvement in our margin, frankly, leading up to the transition.

We were very proactive in terms of not waiting for the transition to happen, we feel we've taken most of the costs out except for those that are remaining, which will disappear in Q1.

Okay. Then a question on the actuarial review, which I always am hesitant to ask about because it could get a little bit technical, but in the LTC component, specifically, was a familiar pattern.

You increase your morbidity reserves essentially and then offset that with future premium increases expected. On the medical cost inflation that you're observing, you talked about higher utilization because of rising healthcare costs.

Is that just another way of saying the utilization is, well, is it actually higher or is it the same utilization and it's just costing you more? Because it's kind of a nuanced message there.

What kind of I guess inflation are you factoring in to this updated assumption, up to 10% a year, something like that? I don't know.

Hi, Gabriel. It's Stephanie.

Thank you for the questions. For the LTC triennial review, what we saw is a modest favorable impact that's in line with the experience that we would have seen since the last review.

As you point out, there were different parts. If we dive in a little deeper, we have been seeing utilization losses for a number of quarters.

To your question, that is a result of higher medical inflation. This is something we were focused on, and we've fully addressed what we've observed, and we also reflecting elevated inflation for a little longer period of time.

There were also, as you point out, other parts that led to positives. We had observed consistent termination gains, which led to a favorable impact to reserve, and we have also reviewed our premium rate increase assumption, which we remain very conservative and embedded less than 30% of the total outstanding ask.

Got it. Any sense of what medical cost inflation you're assuming?

As I mentioned, medical cost inflation has come down since its peak, but it's still slightly elevated. We reflected that that would persist a little longer before returning to our longer-term view.

I think I would leave it with our longer-term view is higher than general inflation expectations.

Thank you. Thanks.

Thanks very much. Good morning.

Question maybe for Phil here. Just the thinking behind this refresh strategy.

You came out with these 2027 targets about 16 months ago. You're standing by them.

Is it really a new team? You wanted to kind of refresh it because you've got a new kind of leadership team?

I noticed that now you're talking about kind of more balanced growth across the portfolio, and I'm just interpreting it. Leave it up to you here to paraphrase.

Investing to grow in Canada and the US, how should we be thinking about that in terms of outlook for share buybacks? They still look like that's going to be fairly robust, but yeah, maybe you can address some of those points I raised.

Thanks.

Thanks, Tom. This is Phil, and there's quite a lot in there to unpack.

If I miss something out, please do call me out on it, and I'll provide a supplement. The logic for the refreshed strategy update, I do acknowledge that the strategy we've had for the past 8 years has served the company tremendously well.

We've been through a period of hugely successful transformation. We felt, having achieved what we wanted to achieve with the last strategy, as a leadership team, we felt that this was the right time to take a fresh look.

Something that I've said before is that given that the external environment continues to evolve, it's really important that strategy is never static, that we always look at what's changing externally and how do we position the company. Yes, of course, to deliver on our 2027 targets, but have a much longer time horizon beyond that when we think about setting the company up for long-term success.

Tom, you picked up on something that's really important, and that is balanced growth and having a diversified organization is something that we truly value. It's something that provides resilience.

One of the things that is not changing as part of this strategy is that Asia and Global Wealth and Asset Management remain compelling growth opportunities, and we will do everything within our means to fulfill that opportunity. At the same time, given the transformation that has been delivered over the course of the past 8 years, our new business footprint in both Canada and the US is attractive.

We're generating attractive margins, and we see an opportunity to invest to grow our new business in the US and Canada, and in particular in the US, to grow new business so that it sustains our scale. That therefore is the relevance, I think, to our overall portfolio diversification.

We sustain a level of diversification within the overall organization. On this topic as well, our strategy clarifies that we do believe that it's important to be in the mega-economies of the future, and we have a hugely successful business in the US, both on the GWM side and on the insurance side with John Hancock.

We have a successful scaled business in China, and where we saw a strategic gap was the scale of our presence in India. That was really the logic for us taking decisive action to enter the India insurance market.

There are other elements of our strategy that I won't go into, but I just call out that being a leader in AI and an AI-powered organization is important to us, and I think that's very important to our overall competitive position and future success. Tom, you referenced the importance of capital generation, and I do want to emphasize that we expect to continue the strong capital generation that the company has seen in recent years.

Colin referenced our expectations for remittances for 2025. I think that's a good example, $6 billion.

When it comes to capital deployment and share buybacks, our highest priority is unchanged, and that's to organically invest in our business, as well as sustaining and growing our shareholder dividend. Then, for what's left over, buybacks and strategic M&A are possibilities.

I will emphasize, when it comes to strategic M&A, the bar is high, and that means that buybacks we expect to continue to be an important form of capital deployment for us. I hope that covers all the points you raised, Tom.

No, that's fulsome. Thank you so much, Phil.

Oh, and congratulations to Marc Costantini as he kind of moves on to his next role here. All the best.

Thanks, Tom.

Hi, good morning. I'm going to go back to the actuarial review, and there was I think a change in methodology in Asia.

Correct me if I'm wrong, from the PPA to the GMM. I think this had a decent positive impact on the CSM.

I'm just trying to understand why the shift and what impact did that shift have on core earnings in the quarter, and with all the moving parts, and the core earnings going forward. Colin, I think you talked a bit about it will have a positive impact.

Can you put a finer point on what that positive impact might be?

Thanks, Doug. It's Stephanie.

I'll start, and see if Colin wants to add. You're right.

In terms of the impact of the annual review, which was favorable and led to reserve reduction of $605 million, a large part of this was driven by a change in how we account for some health insurance contract in Hong Kong. We're moving from the PAA approach, or what you would call short-term insurance contract, to reserving for the lifetime.

I'd add that since we implemented IFRS 17, we've been studying industry practice, and we found that most peers accounted for these products over the lifetime. We're now aligning with this practice.

What this does is we've capitalized all cash flows in the reserve, and we've set up a CSM to offset it. No impact to insurance contract liability.

In terms of the impact to core earning for this item, there are small timing differences, there'll be a modest favorable impact. Then you asked about the impact of the annual review overall on core earnings.

Due to the favorable impact, we saw an increase in CSM, which will lead to an increase in CSM amortization of approximately $30 million per quarter. Okay.

Per quarter. Okay.

Is there any other changes being contemplated?

At this time, with no other changes of this type being contemplated.

Okay. Then just second, on the credit side, thanks for the detail on private credit.

What caught my eye is, it seems like the parameter movements caused a reversal of credit provisions this quarter, and it was kind of tied into the positive move in equity markets. Everyone can see the positive move in equity markets, but I was a bit surprised that positive move in equity markets has an impact on the ECL, or as significant an impact on the ECL.

I just wanted to kind of understand the mechanics there a little bit. Thank you.

Hi, Doug. It's Trevor.

Thanks for the question. Yes, in terms of the ECL, as you noted, there was a $44 million release, which was better than the charge that we saw in Q2.

Just to remind people, the ECL charge is broadly two main components. The first one is basically the impact of defaults and rating changes, which you would expect.

Then there is secondly this modeled impact reflecting changes in the broader economic environment, and we include both of those components in our definition of core earnings. As you said, for Q3 specifically, the majority of the benefit was driven by this positive impact from the market movement impact, or the market environment impact driven by strong equity markets.

I guess to your question, we use a third-party model, and that third-party model basically generates this market environment impact, and it includes a variety of metrics. Equity markets is one, volatility, interest rates, etc., and how those have actually been correlated to credit experience in the past.

That's what the model is basically doing. It's not a linear impact, but given the strength of equity markets and the consistency of that strength, the model obviously picked it up and felt that the environment was obviously much much less risky than it had been in prior quarters, and that leads to the release.

I guess the point is, this obviously was favorable this quarter, but this is another area where, if equity markets were to decline, you could see the reverse happen. I guess that's Yes.

kind of obvious, but

Yes, exactly. Yes.

Yes, that's right. Okay.

Okay. Thank you very much.

Thanks. Good morning.

First question, I want to ask about the Hong Kong APE sales. Obviously, they were quite strong over the prior four quarters and now a little bit of a decline year over year.

Really, I guess what I want to understand is what should we expect over the next few quarters as you continue to lap some pretty good comps? Do you think you can produce positive growth in sales, or is it going to be similar to this quarter, or maybe there's a bit of a, I don't know if you call it a normalization in growth?

Thanks, Paul. It's it's Steve here.

As as you noted, the Hong Kong, the APE was down modestly year over year, and that was off, as Colin noted earlier, a very strong base the prior year. To your point about growth, we've we've seen year to date the APE is increased 46% year over year, so that demonstrates the growth that we've had.

In addition, while the APE declined in the quarter, our value metrics performed strongly. In Hong Kong, we were happy with these results.

NBV and NBCSM were up 10% and 12% year over year, respectively. That was due to some favorable mix, some additional health and protection that we saw in the quarter.

In terms of outlook in in Hong Kong, Q4 was a another strong year last year. We typically see seasonal variability, we'd expect some drop-off in Q4 and picking up again in Q1.

If I back up to, look at the the underlying fundamentals and look a bit further out than that, the the market fundamentals do remain very strong, and demand is is high from our customers. We also see that in Hong Kong, and in Singapore as well, an international financial center, and there's a strong flow of funds.

The the underlying drivers are favorable, and we're making significant investments in our capabilities to support customers and distributors. As we look out over that the medium term, we remain very optimistic about the Hong Kong market.

Yep.

Okay. Second question is going back to the strategy refresh.

I want to get a better sense of how we should think about the earnings trajectory for Canada and US. When I hear investments in those markets, I think about maybe in the short term, higher expenses as a result of those investments, but longer-term growth rates.

Is that the right interpretation?

Hey, Paul, this is Phil, and thanks for the drill-down question there on the strategy. The way I see this, we only have one target when it comes to medium-term earnings growth, and that's the 10% to 12% core EPS.

My expectation, and this is the leadership team's expectation, is that each of our segments contribute to that growth. The lens that we've applied in resetting the strategy is really to make it clear that growth will not only come from Asia and Global WAM, the US and Canada will be important contributors to that.

This is about investing to sustain scale, investing to sustain capital generation, investing to sustain growth rates. I don't want to get too precise or issue any formal guidance, but I think we're not looking double digits for Canada and the US, but it's sort of low to mid single digits for the US and a little higher for Canada.

I think we have great businesses in North America, and this strategy really clarifies that we see those businesses being an ongoing and important part of the overall portfolio.

Yep. Got it.

Thank you. Thank you.

Good morning. Phil, a related question.

When I reflect back on what the US business was in the past and what it's become, I remember, as I suspect many people on the call do, that the US business was a much broader business. Long-term care, universal life, variable annuities, variable universal life.

There was a lot going on, but it was a really messy business as well. As you think about this refresh in the US, is the goal to drive higher sales levels in your existing product mix, or will you return Manulife to its former self with just a much broader product suite in the US?

Thank you, Mario, for the question. Let me be really clear upfront, there is no intention in the US or John Hancock to go back to the days of variable annuities and that higher market risk types of products.

There are really two elements to our strategy, and I'll come on to this. What we're really thinking about is when we reflect on the transformation that we've delivered in the US over the course of the past 7 to 8 years, is we've created differentiation through our focus on behavioral insurance that promotes health and wellness, and that creates differentiation in the market that has enabled us to be successful in what I would say is quite a niche footprint, focusing on the high net worth customer segment.

It's profitable. The business we write is profitable.

The margins are now at a similar level to the margins that we generate on average in Asia. The question for us is twofold.

One is how do we potentially broaden the scope of solutions that we provide to customers, but within our risk appetite, not going back to where we were 10, 15, 20 years ago. Secondly, how do we take the solutions that we have and enable those solutions to be accessed not only by high net worth individuals, but affluent individuals and families and emerging high net worth individuals?

That's really an expansion of the relevant customer segments that we focus on. I feel with some of the strategic changes that we're making in the US and the team that we have, we're very well positioned to be able to deliver on that opportunity and sustain our scale, earnings, and capital generation from what is the largest economy and the largest insurance market in the world.

Phil, does that mean that you stick with your existing product suite? I couldn't quite figure that out.

In the near term, we're sticking with our existing product suite and scaling that or moving that into additional customer segments. We are, to be fully transparent, Mario, also looking at opportunities in adjacent products that help fulfill a wider range of customer needs, but within our risk appetite.

We have robust risk disciplines that apply not only in the US, but around the world.

Okay. Quick follow-up question.

None of this is free. I see that the efficiency target is no longer formally part of your strategic refresh, but I appreciate that it's still a priority.

Would it be fair to say that the sub-45% efficiency ratio, that's something you could sacrifice in the near term in pursuit of this refresh strategy in Canada and the US?

Actually, Mario, we're not withdrawing our sub-45% targets when it comes to efficiency ratio. I expect that to be maintained.

Going in the other direction on this, yes, we'll be investing in our businesses, but part of our investments at an enterprise level include becoming an AI-powered organization, and we're already seeing the benefits of our investments and leadership position in AI payoff when it comes to mitigating expense growth and providing an ability for the organization to do more with less. I think there are forces moving in both directions that will enable us to continue to be efficient.

That makes sense. Thank you.

Marc, congratulations on a great career there, and hope to see you in your new role. He's

smiling. Thanks, Mario.

Great.

Hi, thank you. Good morning.

Just a real quick question on Corporate. There's a bit of noise in there.

You actually have a negative CSM. Colin, how should I think about this business unit on a go-forward basis from a margin perspective?

Hey, Darko. Good to hear from you.

Corporate was different to the trend, actually, and a large part of that was the withholding tax accrual release that we made in respect of the CQS acquisition. I think going forward, you would expect us to have a result of $300 to $400 million in this line, and that reflects further investments in central products.

You mentioned the negative CSM. That is related to our COLI product that we've owned for many years.

It's really just a intercompany settlement, and nothing to really focus on. It will be steady for the next few quarters.

Okay. Thank you.

A question for Steve Finch. Steve, the question is really twofold.

One is your agent count still declining? Maybe you can talk a little bit about what it is you're doing there and if does it affect sales power?

Then on top of that, just quickly, how should we think about the build-out of India in terms of the earnings drag for the next couple of years? Thanks.

Thanks, Darko. On the agency side, our strategy is building out high-quality and professional agency, and it's not really driven by that metric in terms of number of agents.

If we look at other metrics in terms of top-tier agency, our APE per active agent is growing significantly. Our NBV per agent is also growing materially, and we've seen growth in our agency sales this year as a result of this.

One of the other objective measures there is Million Dollar Round Table. Manulife was third globally in terms of number of MDRT qualifiers in '24, and the run rate is in the 20s, 20% for growth tracking through 2025 as well.

What we're continuing to do to drive this is we're making investments. Broadly speaking, those investments are training and development, really investing in our people to be able to recruit high-quality agents, train them very well, develop them into leaders, and create highly professional agents, along with investments in technology and tools, AI tools that are making the agents more efficient, providing better service to our customers, identifying from all the data that we've got on customer interactions what the next best need for the agent would be.

We're seeing benefits from these investments, we are pleased with what we're seeing come out of these investments in the agency strategy. It is the core distribution engine of the franchise, representing a little over a third of the sales.

Steve, did you want to cover the India earnings question, or do you want Oh, no, it's a question for Phil. You go ahead, Steve.

Thanks. As Phil said earlier, we still have a ways to go to get the entity set up.

We're not giving those forward projections at this time in terms of financial metrics, but we look forward to updating on that in the future.

That makes sense. Just to supplement, in terms of one financial metric we can provide is, we expect the capital cost of India over the course of the next decade to be around $400 million US dollars capital injection.

In the first 5 years, that's around $140 to $150 million US dollars. I think that helps really to put some parameters around what the overall financial dynamics are.

A hugely exciting move for Manulife.

Great. Thank you very much.

Thank you, operator. We'll be available after the call if there are any follow-up questions.

Have a good day, everyone.